ERBB2 and breast cancer: In another study on 58 BC patients, we identified all the somatic, non-silent, base substitution, and indel mutations per megabase of the examined genome to calculate the tumor mutation burden (TMB) and established an Egyptian TMB prediction model based on the expression level of ER, PR, HER-2, and Ki-67 [17].